Light Mode
$0.0315 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0315, and at the day’s high of $0.0325
+0.01 (+71.96%) / 6M
Momentum, market sentiment, and recent alerts
ADAPY reads very good: price sits above both the 20- and 200-day averages, the 12-month move is -37.5%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.